

Genitourinary Drugs-EMEA Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/G3328D64953EN.html

Date: February 2018

Pages: 138

Price: US\$ 3,480.00 (Single User License)

ID: G3328D64953EN

Abstracts

Report Summary

Genitourinary Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Genitourinary Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Genitourinary Drugs 2013-2017, and development forecast 2018-2023

Main market players of Genitourinary Drugs in EMEA, with company and product introduction, position in the Genitourinary Drugs market

Market status and development trend of Genitourinary Drugs by types and applications Cost and profit status of Genitourinary Drugs, and marketing status Market growth drivers and challenges

The report segments the EMEA Genitourinary Drugs market as:

EMEA Genitourinary Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe Middle East Africa

EMEA Genitourinary Drugs Market: Product Type Segment Analysis (Consumption



Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Sex Hormones
Urologicals
Genitourinary Anti-Infectives
Gynaecologicals

EMEA Genitourinary Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Genitourinary Cancer

Bladder Cancer

Cervical Cancer

Kidney/Renal Cancer

Ovarian Cancer

Prostate Cancer

EMEA Genitourinary Drugs Market: Players Segment Analysis (Company and Product introduction, Genitourinary Drugs Sales Volume, Revenue, Price and Gross Margin):

Astellas

Pfizer

GlaxoSmithKline

Eli Lilly

Bayer AG

Merck

Abbott Laboratories

Bristol-Myers Squibb

Genentech

Roche

Amgen

Botex

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF GENITOURINARY DRUGS

- 1.1 Definition of Genitourinary Drugs in This Report
- 1.2 Commercial Types of Genitourinary Drugs
 - 1.2.1 Sex Hormones
 - 1.2.2 Urologicals
 - 1.2.3 Genitourinary Anti-Infectives
 - 1.2.4 Gynaecologicals
- 1.3 Downstream Application of Genitourinary Drugs
 - 1.3.1 Genitourinary Cancer
 - 1.3.2 Bladder Cancer
- 1.3.3 Cervical Cancer
- 1.3.4 Kidney/Renal Cancer
- 1.3.5 Ovarian Cancer
- 1.3.6 Prostate Cancer
- 1.4 Development History of Genitourinary Drugs
- 1.5 Market Status and Trend of Genitourinary Drugs 2013-2023
 - 1.5.1 EMEA Genitourinary Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Genitourinary Drugs Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Genitourinary Drugs in EMEA 2013-2017
- 2.2 Consumption Market of Genitourinary Drugs in EMEA by Regions
 - 2.2.1 Consumption Volume of Genitourinary Drugs in EMEA by Regions
 - 2.2.2 Revenue of Genitourinary Drugs in EMEA by Regions
- 2.3 Market Analysis of Genitourinary Drugs in EMEA by Regions
 - 2.3.1 Market Analysis of Genitourinary Drugs in Europe 2013-2017
 - 2.3.2 Market Analysis of Genitourinary Drugs in Middle East 2013-2017
 - 2.3.3 Market Analysis of Genitourinary Drugs in Africa 2013-2017
- 2.4 Market Development Forecast of Genitourinary Drugs in EMEA 2018-2023
 - 2.4.1 Market Development Forecast of Genitourinary Drugs in EMEA 2018-2023
 - 2.4.2 Market Development Forecast of Genitourinary Drugs by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

3.1 Whole EMEA Market Status by Types



- 3.1.1 Consumption Volume of Genitourinary Drugs in EMEA by Types
- 3.1.2 Revenue of Genitourinary Drugs in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Europe
 - 3.2.2 Market Status by Types in Middle East
 - 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Genitourinary Drugs in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Genitourinary Drugs in EMEA by Downstream Industry
- 4.2 Demand Volume of Genitourinary Drugs by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Genitourinary Drugs by Downstream Industry in Europe
 - 4.2.2 Demand Volume of Genitourinary Drugs by Downstream Industry in Middle East
 - 4.2.3 Demand Volume of Genitourinary Drugs by Downstream Industry in Africa
- 4.3 Market Forecast of Genitourinary Drugs in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF GENITOURINARY DRUGS

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Genitourinary Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 GENITOURINARY DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Genitourinary Drugs in EMEA by Major Players
- 6.2 Revenue of Genitourinary Drugs in EMEA by Major Players
- 6.3 Basic Information of Genitourinary Drugs by Major Players
- 6.3.1 Headquarters Location and Established Time of Genitourinary Drugs Major Players
- 6.3.2 Employees and Revenue Level of Genitourinary Drugs Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 GENITOURINARY DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA



7.1 Astellas

- 7.1.1 Company profile
- 7.1.2 Representative Genitourinary Drugs Product
- 7.1.3 Genitourinary Drugs Sales, Revenue, Price and Gross Margin of Astellas

7.2 Pfizer

- 7.2.1 Company profile
- 7.2.2 Representative Genitourinary Drugs Product
- 7.2.3 Genitourinary Drugs Sales, Revenue, Price and Gross Margin of Pfizer
- 7.3 GlaxoSmithKline
 - 7.3.1 Company profile
 - 7.3.2 Representative Genitourinary Drugs Product
- 7.3.3 Genitourinary Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline

7.4 Eli Lilly

- 7.4.1 Company profile
- 7.4.2 Representative Genitourinary Drugs Product
- 7.4.3 Genitourinary Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly

7.5 Bayer AG

- 7.5.1 Company profile
- 7.5.2 Representative Genitourinary Drugs Product
- 7.5.3 Genitourinary Drugs Sales, Revenue, Price and Gross Margin of Bayer AG

7.6 Merck

- 7.6.1 Company profile
- 7.6.2 Representative Genitourinary Drugs Product
- 7.6.3 Genitourinary Drugs Sales, Revenue, Price and Gross Margin of Merck

7.7 Abbott Laboratories

- 7.7.1 Company profile
- 7.7.2 Representative Genitourinary Drugs Product
- 7.7.3 Genitourinary Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories

Laboratorioo

- 7.8 Bristol-Myers Squibb
 - 7.8.1 Company profile
 - 7.8.2 Representative Genitourinary Drugs Product
- 7.8.3 Genitourinary Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb

7.9 Genentech

- 7.9.1 Company profile
- 7.9.2 Representative Genitourinary Drugs Product



- 7.9.3 Genitourinary Drugs Sales, Revenue, Price and Gross Margin of Genentech
- 7.10 Roche
 - 7.10.1 Company profile
 - 7.10.2 Representative Genitourinary Drugs Product
 - 7.10.3 Genitourinary Drugs Sales, Revenue, Price and Gross Margin of Roche
- 7.11 Amgen
 - 7.11.1 Company profile
 - 7.11.2 Representative Genitourinary Drugs Product
 - 7.11.3 Genitourinary Drugs Sales, Revenue, Price and Gross Margin of Amgen
- 7.12 Botex
 - 7.12.1 Company profile
 - 7.12.2 Representative Genitourinary Drugs Product
- 7.12.3 Genitourinary Drugs Sales, Revenue, Price and Gross Margin of Botex

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF GENITOURINARY DRUGS

- 8.1 Industry Chain of Genitourinary Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF GENITOURINARY DRUGS

- 9.1 Cost Structure Analysis of Genitourinary Drugs
- 9.2 Raw Materials Cost Analysis of Genitourinary Drugs
- 9.3 Labor Cost Analysis of Genitourinary Drugs
- 9.4 Manufacturing Expenses Analysis of Genitourinary Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF GENITOURINARY DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
- 10.2.2 Brand Strategy
- 10.2.3 Target Client
- 10.3 Distributors/Traders List



CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: Genitourinary Drugs-EMEA Market Status and Trend Report 2013-2023

Product link: https://marketpublishers.com/r/G3328D64953EN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G3328D64953EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970